That O/S of 131M was after the offering. The final pricing, once they issued the "units" of either common stock and 2 warrants or a pre-funded warrant with 2 other warrant, and each got Class C warrants which were essentially free and a hedge against the offering price vs the PPS on the market, was just over a nickel. The company was being delisted and tanking, so those Class C warrants protected the investors. It's all described here on page 4: https://www.sec.gov/Archives/edgar/data/0001534287/000156459018007185/bioa-10k_20171231.htm
And, once again, Naxos didn't own BioAmber, so they didn't sell it. That crap came from this 3rd party presentation on section 363 sales and was completely wrong on what happened to BioAmber:
News 
Market Data 
Discover 
